Table 2.

CAR-NK vs CAR-T cell therapy.

Cellular therapy	Target antigens	Advantages	Disadvantages
CAR-T	Surface TAAs	- Potent cytotoxicity - Durable clinical response - Single infusion - Long-term benefit due to ‘‘living drug” nature	- High relapse rate - Mainly autologous - CRS - Neurotoxicity - Poor tumor trafficking capacity - High cost
CAR-NK	Surface TAAs	- High safety profile with no CRS, neurotoxicity, and GvHD in an allogenic setting - Inherent antitumor functionality - Off-the-shelf manufacturing	- Resistance to genetic engineering - Poor tumor trafficking capacity - Requiring more clinically demonstrated efficacy